Search Results - "Lebranchu, Y"

Epidemiology of Posttransplant Lymphoproliferative Disorders in Adult Kidney and Kidney Pancreas Recipients: Report of the French Registry and Analysis of Subgroups of Lymphomas by Caillard, S., Lamy, F. X., Quelen, C., Dantal, J., Lebranchu, Y., Lang, P., Velten, M., Moulin, B

“…A registry of posttransplant lymphoproliferative disorders (PTLD) was set up for the entire population of adult kidney transplant recipients in France. Cases…”
Get full text

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients by Humar, A., Lebranchu, Y., Vincenti, F., Blumberg, E. A., Punch, J. D., Limaye, A. P., Abramowicz, D., Jardine, A. G., Voulgari, A. T., Ives, J., Hauser, I. A., Peeters, P.

“…Late‐onset cytomegalovirus (CMV) disease is a significant problem with a standard 3‐month prophylaxis regimen. This multicentre, double‐blind, randomized…”
Get full text

Reduction of Extended‐Release Tacrolimus Dose in Low‐Immunological‐Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor‐Specific Antibodies: A Randomized Study by Gatault, P., Kamar, N., Büchler, M., Colosio, C., Bertrand, D., Durrbach, A., Albano, L., Rivalan, J., Le Meur, Y., Essig, M., Bouvier, N., Legendre, C., Moulin, B., Heng, A.‐E., Weestel, P.‐F., Sayegh, J., Charpentier, B., Rostaing, L., Thervet, E., Lebranchu, Y.

“…The aim of this study (ClinicalTrials.gov, NCT01744470) was to determine the efficacy and safety of two different doses of extended‐release tacrolimus (TacER)…”
Get full text

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome by Legendre, C.M, Licht, C, Muus, P, Greenbaum, L.A, Babu, S, Bedrosian, C, Bingham, C, Cohen, D.J, Delmas, Y, Douglas, K, Eitner, F, Feldkamp, T, Fouque, D, Furman, R.R, Gaber, O, Herthelius, M, Hourmant, M, Karpman, D, Lebranchu, Y, Mariat, C, Menne, J, Moulin, B, Nürnberger, J, Ogawa, M, Remuzzi, G, Richard, T, Sberro-Soussan, R, Severino, B, Sheerin, N.S, Trivelli, A, Zimmerhackl, L.B, Goodship, T, Loirat, C

“…This article describes the use of eculizumab in patients with atypical hemolytic–uremic syndrome. This C5 inhibitor was associated with improvement in…”
Get full text

Can We Eliminate Both Calcineurin Inhibitors and Steroids? by Lebranchu, Y

“…Abstract Calcineurin inhibitors (CNIs) and steroids, the cornerstone of most immunosuppressive regimens in the past 20 years, have undesirable chronic effects…”
Get full text

Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study by Lebranchu, Y., Thierry, A., Toupance, O., Westeel, P. F., Etienne, I., Thervet, E., Moulin, B., Frouget, T., Le Meur, Y., Glotz, D., Heng, A‐E., Onno, C., Buchler, M., Girardot‐Seguin, S., De Ligny, B. Hurault

“…Sirolimus (SRL) allows to minimize the use of cyclosporine (CsA), but de novo administration after transplantation is associated with various complications. We…”
Get full text

The Role of Organic Anion-Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics by Picard, N, Yee, S W, Woillard, J‐B, Lebranchu, Y, Le Meur, Y, Giacomini, K M, Marquet, P

“…The goal of this study was to determine the roles of the organic anion–transporting polypeptides (OATPs) OATP1A2, OATP1B1, and OATP1B3 and their genetic…”
Get full text

New Approaches to De Novo Immunosuppression and Steroid Elimination by Lebranchu, Y

“…Abstract Calcineurin inhibitors (CNIs) and steroids, the cornerstone of most immunosuppressive regimens in the past 20 years, have undesirable long-term side…”
Get full text

Genome‐Wide Association Study of Acute Renal Graft Rejection by Ghisdal, L., Baron, C., Lebranchu, Y., Viklický, O., Konarikova, A., Naesens, M., Kuypers, D., Dinic, M., Alamartine, E., Touchard, G., Antoine, T., Essig, M., Rerolle, J. P., Merville, P., Taupin, J. L., Le Meur, Y., Grall‐Jezequel, A., Glowacki, F., Noël, C., Legendre, C., Anglicheau, D., Broeders, N., Coppieters, W., Docampo, E., Georges, M., Ajarchouh, Z., Massart, A., Racapé, J., Abramowicz, D., Abramowicz, M.

“…Acute renal rejection is a major risk factor for chronic allograft dysfunction and long‐term graft loss. We performed a genome‐wide association study to detect…”
Get full text

High Dose Epoetin Beta in the First Weeks Following Renal Transplantation and Delayed Graft Function: Results of the Neo‐PDGF Study by Martinez, F., Kamar, N., Pallet, N., Lang, P., Durrbach, A., Lebranchu, Y., Adem, A., Barbier, S., Cassuto‐Viguier, E., Glowaki, F., Le Meur, Y., Rostaing, L., Legendre, C., Hermine, O., Choukroun, G.

“…Erythropoietin promotes nephroprotection in animal models of ischemia‐reperfusion injury. Neorecormon® and Prevention of Delayed Graft Function (Neo‐PDGF) is a…”
Get full text

Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF—Four‐Year Results of the Postconcept Study by Lebranchu, Y., Thierry, A., Thervet, E., Büchler, M., Etienne, I., Westeel, P. F., de Ligny, B. Hurault, Moulin, B., Rérolle, J. P., Frouget, T., Girardot‐Seguin, S., Toupance, O.

“…Calcineurin inhibitor (CNI) withdrawal has been used as a strategy to improve renal allograft function. We previously reported that conversion from…”
Get full text

Intravenous Immunoglobulins in the Prevention of Rejection of a Second or Third Kidney Graft by Glotz, D., Rostaing, L., Merville, P., Squifflet, J.-P., Lebranchu, Y.

“…Intravenous immunoglobulin (IVIg) reduces acute rejection episodes in kidney transplantation, but adverse events (AEs) are common. The aim of this study was to…”
Get full text

New Approaches to De Novo Immunosuppression and Steroid Elimination by Lebranchu, Y

“…Abstract Calcineurin inhibitors (CNIs) and steroids, the cornerstones of most immunosuppressive regimens over the past 20 years, have undesirable chronic side…”
Get full text

Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6‐Month Course of Steroids by Büchler, M., Caillard, S., Barbier, S., Thervet, E., Toupance, O., Mazouz, H., Hurault de Ligny, B., Le Meur, Y., Thierry, A., Villemain, F., Heng, A.‐E., Moulin, B., Morin, M. P., Noël, C., Lebranchu, Y.

“…To evaluate the efficacy and tolerance of a calcineurin inhibitor (CNI)‐free regimen, 145 renal recipients were prospectively randomized to receive either…”
Get full text

Immunosuppressant Regimen Based on Sirolimus Decreases Aortic Stiffness in Renal Transplant Recipients in Comparison to Cyclosporine by Joannidès, R., Monteil, C., de Ligny, B. H., Westeel, P. F., Iacob, M., Thervet, E., Barbier, S., Bellien, J., Lebranchu, Y., Seguin, S. G., Thuillez, C., Godin, M., Etienne, I.

“…Whether or not a cyclosporine A (CsA)‐free immunosuppressant regimen based on sirolimus (SRL) prevents aortic stiffening and improves central hemodynamics in…”
Get full text

Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor by Gouilleux‐Gruart, V., Chapel, H., Chevret, S., Lucas, M., Malphettes, M., Fieschi, C., Patel, S., Boutboul, D., Marson, M.‐N., Gérard, L., Lee, M., Watier, H., Oksenhendler, E., Galicier, L., Fermand, J.P., Viallard, J.F., Jaccard, A., Hoarau, C., Lebranchu, Y., Bérezné, A., Mouthon, L., Karmochkine, M., Georgin‐Lavialle, S., Schleinitz, N., Durieu, I., Nove‐Josserand, R., Chanet, V., Le‐Moing, V., Just, N., Salanoubat, C., Jaussaud, R., Suarez, F., Hermine, O., Solal‐Celigny, P., Hachulla, E., Sanhes, L., Gardembas, M., Pellier, I., Tisserant, P., Pavic, M., Bonnotte, B., Haroche, J., Amoura, Z., Alric, L., Thiercelin, M.F., Tetu, L., Adoue, D., Bordigoni, P., Perpoint, T., Sève, P., Rohrlich, P., Pasquali, J.L., Soulas, P., Couderc, L.J., Catherinot, E., Giraud, P., Baruchel, A., Deleveau, I., Chaix, F., Donadieu, J., Tron, F., Larroche, C., Blanc, AP, Masseau, A., Hamidou, M., Kanny, G., Morisset, M., Millot, F., Fain, O., Borie, R., Perlat, A., Martinez, V., Bienvenu, B., Debré, P., Mouillot, G., Théodorou, I., Rabian, C., Carmagnat, M., Vince, N., Bono, C.

“…Summary Treatment of common variable immunodeficiency disorders (CVID) is based on replacement therapy using intravenous (i.v.) or subcutaneous (s.c.)…”
Get full text

Five‐Year Results of a Randomized Trial Comparing De Novo Sirolimus and Cyclosporine in Renal Transplantation: The Spiesser Study by Lebranchu, Y., Snanoudj, R., Toupance, O., Weestel, P.‐F., de Ligny, B. Hurault, Buchler, M., Rerolle, J.‐P., Thierry, A., Moulin, B., Subra, J.‐F., Deteix, P., Pogamp, P. Le, Finzi, L., Etienne, I.

“…Calcineurin inhibitors improve acute rejection rates and short‐term graft survival in renal transplantation, but their continuous use may be deleterious. We…”
Get full text

CMV Infection in the Donor and Increased Kidney Graft Loss: Impact of Full HLA‐I Mismatch and Posttransplantation CD8+ Cell Reduction by Gatault, P., Halimi, J‐M., Forconi, C., Thibault, G., Barbet, C., Mérieau, E., Gaudy‐Graffin, C., Marlière, J‐F., Goudeau, A., Bruyère, F., Lebranchu, Y., Büchler, M., Baron, C.

“…Despite a large body of literature, the impact of chronic cytomegalovirus (CMV) infection in donor on long‐term graft survival remains unclear, and factors…”
Get full text

Exclusion of Patients with a Severe T-Cell Defect Improves the Definition of Common Variable Immunodeficiency by Bertinchamp, Rémi, MD, Gérard, Laurence, MD, Boutboul, David, MD, Malphettes, Marion, MD, Fieschi, Claire, MD, PhD, Oksenhendler, Eric, MD

“…Background In 2014, the European Society for Immune Deficiencies (ESID) revised the common variable immunodeficiency (CVID) diagnosis criteria by incorporating…”
Get full text

Early Pulse Pressure and Low‐Grade Proteinuria as Independent Long‐Term Risk Factors for New‐Onset Diabetes Mellitus After Kidney Transplantation by Roland, M., Gatault, P., Al‐Najjar, A., Doute, C., Barbet, C., Chatelet, V., Laouad, I., Marlière, J.‐F., Nivet, H., Büchler, M., Lebranchu, Y., Halimi, J.‐M.

“…Risk factors for new‐onset diabetes after transplantation (NODAT) need to be assessed in large cohorts. We retrospectively evaluated the impact of early (3 and…”
Get full text